8121
-
Drug Design, Development and Therapy
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Real benefits for authors, including fast-track processing of papers.
Drug Design, Development and Therapy
(592,466) Views
Editor in Chief Daniel S Pilch, PhD
1177-8881
ReviewReview of the pharmacology and clinical studies of micafungin
Alison M Bormann, Vicki A Morrison
Drug Design, Development and Therapy 2009, 3:295-302
10 December 2009
Original Research
Effect of combinations of antiviral drugs on herpes simplex encephalitis
Bryan M Gebhardt, Federico Focher, Richard Eberle, et al
Drug Design, Development and Therapy 2009, 3:289-294
09 December 2009
Review
Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent
Brian Casserly, James R Klinger
Drug Design, Development and Therapy 2009, 3:269-287
30 November 2009
Review
Conivaptan and its role in the treatment of hyponatremia
Jalal K Ghali, Jareer O Farah, Suleiman Daifallah, et al
Drug Design, Development and Therapy 2009, 3:253-268
16 October 2009
Review
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
Ann Janssens, Marc Boogaerts, Gregor Verhoef
Drug Design, Development and Therapy 2009, 3:241-252
14 October 2009
Review
A review of exenatide as adjunctive therapy in patients with type 2 diabetes
Gisela I Robles, Devada Singh-Franco
Drug Design, Development and Therapy 2009, 3:219-240
10 September 2009
Case report
Long-term disease-free survivor of metastatic large-cell neuroendocrine carcinoma of the lung treated with amrubicin and irinotecan
Shinichiro Ryuge, Shi-Xu Jiang, Mayuko Wada, Ken Katono, et al.
Drug Design, Development and Therapy 2009, 3:213-217
13 July 2009
Original Research
T10B9 monoclonal antibody: A short-acting nonstimulating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection
Thomas H Waid, John S Thompson, Maria Siemionow, Stephen A Brown
Drug Design, Development and Therapy 2009, 3:205-212
25 June 2009
Review
Pleiotropic vasoprotective effects of statins: The chicken or the egg?
Dimitrios Kirmizis, Dimitrios Chatzidimitriou
Drug Design, Development and Therapy 2009, 3:191-204
10 June 2009
Review
Characteristics of doripenem: a new broad-spectrum antibiotic
Francisco Alvarez-Lerma, Santiago Grau, Olivia Ferrández
Drug Design, Development and Therapy 2009, 3:173-190
27 May 2009
Review
Management of advanced breast cancer with the epothilone B analog, ixabepilone
William Gradishar
Drug Design, Development and Therapy 2009, 3:163-171
02 June 2009
Review
Oxybutynin extended release for the management of overactive bladder: a clinical review
AM Arisco, EK Brantly, SR Kraus
Drug Design, Development and Therapy 2009, 3:151-161
26 May 2009
Original Research
Efficacy of epicutaneous Diractin® (ketoprofen in Transfersome® gel) for the treatment of pain related to eccentric muscle contractions
Matthias Rother, Egbert J Seidel, Priscilla M Clarkson, Stefan Mazgareanu, et al.
Drug Design, Development and Therapy 2009, 3:143-149
19 May 2009
Review
Indiplon in the management of insomnia
Michael D Lemon, Joe D Strain, Annie M Hegg, Debra K Farver
Drug Design, Development and Therapy 2009, 3:131-142
08 May 2009
Review
Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex
Sorin J Brull, Mohamed Naguib
Drug Design, Development and Therapy 2009, 3:119-129
24 April 2009
Review
Safety and tolerability of bosentan in the management of pulmonary arterial hypertension
Kari E Roberts, Ioana R Preston
Drug Design, Development and Therapy 2009, 3:111-118
31 March 2009
Rapid Communication
Oxidative stress-induced cell cycle blockage and a protease-independent programmed cell death in microaerophilic Giardia lamblia
Esha Ghosh, Arjun Ghosh, Amar Nath Ghosh, Tomoyoshi Nozaki, Sandipan Ganguly
Drug Design, Development and Therapy 2009, 3:103-110
26 March 2009
Review
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
Ronan Swords, Devalingam Mahalingam, Swaminathan Padmanabhan, Jennifer Carew, Francis Giles
Drug Design, Development and Therapy 2009, 3:89-101
27 March 2009
Original Research
Troglitazone reverses the multiple drug resistance phenotype in cancer cells
Gerald F Davies, Bernhard HJ Juurlink, Troy AA Harkness
Drug Design, Development and Therapy 2009, 3:79-88
17 March 2009
Review
Newer treatments for decompensated heart failure: focus on levosimendan
Ferenc Follath
Drug Design, Development and Therapy 2009, 3:73-78
12 March 2009
Original Research
Analysis of HSP90-related folds with MED-SuMo classification approach
Olivia Doppelt-Azeroual, Fabrice Moriaud, François Delfaud, Alexandre G de Brevern
Drug Design, Development and Therapy 2009, 3:59-72
26 February 2009
Review
Alitretinoin – its use in intractable hand eczema and other potential indications
Bibi Petersen, Gregor BE Jemec
Drug Design, Development and Therapy 2009, 3:51-57
05 February 2009
Review
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
Phuong-Thu T Pham, Gerald S Lipshutz, Phuong-Truc T Pham, Joseph Kawahji, Jennifer S Singer, Phuong-Chi T Pham
Drug Design, Development and Therapy 2009, 3:41-49
23 December 2008
Review
Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases
Thomas J Polascik
Drug Design, Development and Therapy 2009, 3:27-40
22 December 2008
Original Research
Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model
Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al
Drug Design, Development and Therapy 2009, 3:17-26
17 December 2008
Review
Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
Akito Natsume, Rinpei Niwa, Mitsuo Satoh
Drug Design, Development and Therapy 2009, 3:7-16
16 December 2008
Review
Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty
Katherine A Lewis, Erica A Eugster
Drug Design, Development and Therapy 2009, 3:1-5
23 December 2008
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
